인류 노령화로 노화 질환 치료의 중요성이 높아지고 있는 가운데 노화 질환 치료제 개발 기업 하플사이언스(대표 최학배·김대경)가 머니투데이가 주최하는 '2020 제6회 대한민국 산업대상'의 '바이오대상' 수상 업체로 선정됐다...
Science of Aging
Aging - 1. Aging in humans
As the costs needed to care for our aging population continue to increase, more long-term and proactive research focusing on geriatric diseases is needed to ensure a sustainable and vibrant socioeconomic future. Today, many leading pharmaceutical companies are investing tremendous efforts and resources in the development of drugs that can prevent and cure various geriatric diseases.
Aging - 2. Age-related Diseases
Aged cells are normally removed by the body’s immune system. However, as the body’s physiological capacity and immune system weakens as we grow older, aged cells begin to accumulate in the major tissues and organs. These accumulating aged cells create a sustained inflammatory environment, damaging neighboring tissues and causing various degenerative diseases that affect health and well-being.
A research team at the Mayo Clinic has coined the term ‘senolytics’ as a new term for drugs that can delay this process. They have also selected dasatinib (an anticancer drug) and quercetin (an anti-inflammatory drug) as candidate drugs for the field of senolytics.
Experiments using genetically modified mice have demonstrated that the artificial removal of aged cells from the body may increase life expectancy by 35% and alleviate geriatric diseases. However, the molecular mechanisms involved in the relationship between aged cells and the recovery of homeostasis (the ‘natural state’) have yet to be fully understood. Serious interest and research into this topic has only just begun, together with the discovery and development of drugs that can selectively eliminate aged cells or rejuvenate them.
For example, Calico, a healthcare company launched by Google, has been aggressively focusing on identifying solutions to geriatric diseases since its establishment. Following this trend, many other companies have recently been founded to promote research and development in aging and geriatric diseases.
Meanwhile, Juvenescence, a company established by a British billionaire in 2017, in-licensed a candidate drug from the Buck Institute for Research on Aging in the United States. In early 2019, Juvenescence also invested in AgeX Therapeutics and LyGenesis to broaden its research and investment portfolio.
In South Korea, the prevalence of chronic diseases continues to skyrocket, leading to significant increases in government health expenditure. Approximately 94% of the elderly population suffers from at least one chronic disease, and nearly 70% of those aged 65 and older suffer from three or more diseases simultaneously.
Unmet medical needs are more common in the elderly, which negatively impacts their quality of life.
Major geriatric chronic diseases include cardio-cerebrovascular diseases (e.g. hypertension, stroke), musculoskeletal diseases (e.g. arthritis, osteoporosis), and respiratory diseases (e.g. asthma, COPD). Diseases related to the endocrine system (e.g. diabetes), nervous system (e.g. Alzheimer’s), and degeneration of the skin and hair are also included.
Among the most common geriatric diseases, many including osteoarthritis, COPD, dementia, aging of the skin, and hair loss do not have effective treatments available. For this reason, new drugs to treat these conditions are urgently needed.
Aging - 3. Aging and the Extracellular Matrix (ECM)
- The ECM is composed of various structural components (collagen, elastin, hyaluronic acid), binding proteins (proteoglycans, glycoproteins) and growth factors
- The components and structure of the ECM depends on the type of tissue. Cartilage is a ligament with high levels of collagen and contains glycosaminoglycans such as hyaluronic acid to maintain high elasticity during tensile and compressive stress
- Tissues can be categorized into three major types: soft tissue (brain, spinal cord), elastic tissue (muscle, blood vessel), and hard tissue (bone, tooth) depending on how they connect with the ECM components
- The binding proteins in the cell play important regulatory roles in proliferation, growth, and death
- The concentration of ECM components decreases with aging, leading to a negative impact on homeostasis and important properties including the adhesive and repairing capacity of tissue
- Fibroblasts in aged tissue can stop proliferating and growing, leading to a gradual reduction in total cell numbers
Aging - 4. Aging of the skin
Fibroblasts synthesize collagen and hyaluronic acid, both of which are key extracellular matrix (ECM) components. Fibroblasts play a very important role in forming a structural framework within body tissues, and specialize in the maintenance of homeostasis by maintaining tissue integrity.
Some fibroblasts transform into adipocytes (fat cells) beneath the epidermis and dermis, helping the skin to appear more plump and youthful.
As the body ages and exposure to sunlight increases, the number and extent to which these fibroblasts proliferate decreases.
- Loss of rete ridges and dermal papilla between the epidermis and dermis
- Reductions and qualitative changes in collagen and elastin and elastin
- Hormone imbalances
- Weakening of adhesion between the epidermis and dermis
- Increase in the skin’s surface area
- Loss of capillary loops of dermal papillae
- Prolongation of the time required to replace epidermal cells
- Reduced secretive capacity of sweat glands and oil glands
- Drier skin
- Increased pore sizes
- Reduced immune function
Aging - 5. Aging of Joints
- Collagen type II, IX, XI → tensile strength
- Aggrecan → compressive stiffness
- Integrin Receptor → Cell-ECM Interactions
- The reduction in functional cartilage cells and degeneration of ECM components accompanied by aging reduces the flexibility of the joint, causing damage and pain
- The major biochemical factor causing degeneration in the articular cartilage is the inability to balance anabolism and catabolism between ECM components such as type II collagen and proteoglycan.
Aging - 6. Aging of hair follicles
Process of hair production
- HHGMCs receive nutritive components via the capillary near the hair papilla
- Division and proliferation of the HHGMCs directly leads to the production of new cells and hair growth
- These cells gradually move further away from the capillary, and are pushed outside the skin before undergoing programmed cell death
- The cells desiccate after they emerge from the scalp, forming hair
A new therapeutic paradigm for the treatment of diseases with significant unmet needs that
naturally occur with aging
- Normalization of the extracellular matrix structure and rejuvenation of the aged cells
Maintenance of a long term monopoly position
- Difficulties in appearance of replaceable drugs due to their innovative mechanisms
- Preoccupying the leadership in the development of improved similar products
Accelerated development of a series of novel therapies as part of an innovative platform technology approach
- New therapies to treat aging and degeneration of the extracellular matrix.
As the body ages, the connective tissue in each organ weakens, causing a broad range of diseases. Treating the weakened connective tissue is thus considered the most important factor in addressing many geriatric diseases.However, these types of fundamental treatments have largely proven elusive to drug researchers.By seeking to normalize the aging connective tissues, HaplnScience will provide a new approach to the treatment of connective tissue degeneration.
Novel drug that treats the root cause of osteoarthritis
TGF-β signaling is a core physiological and pathological factor involved in the emergence and potential treatment of osteoarthritis.In order to treat and prevent osteoarthritis, it is imperative that Smad2/3 pathway is selectively activated. HS-101 is being developed as a promising first-in-class drug with this mechanism
COPD (Chronic Obstructive Pulmonary Disease) Drug
COPD (Chronic Obstructive Pulmonary Disease) is a respiratory disease that causes obstructed airflow, accompanying pulmonary tissue damage and abnormal inflammatory response, likely leading to emphysema, chronic bronchitis, and asthma. Aging and smoking are the most common causes of COPD.
As current COPD treatments focus on symptom relief such as relieving inflammation and bronchial dilation, there is a high unmet medical need for fundamental treatment that can regenerate and restore damaged pulmonary tissue.
HS-401 is believed to be the fundamental therapy to normalize lung function by strengthening ECM integrity of pulmonary tissues leading to restoring damaged & degenerated elastin fibers.
Novel drug that rejuvenates aging skin
Botox and hyaluronic fillers are known for their efficacy in the treatment of wrinkles. However, they have the following problems:
- Patients can have an unnatural appearance
- Requires top-up surgical procedures every 3 to 6 months
- Repeated procedures cause inconvenience and pain
HS-201 will fundamentally improve upon these problems by:
- Returning the skin to its young, natural and healthy state
- Reducing the inconvenience of multiple surgical procedures
- Maintaining the improved appearance of the skin for a sustained period of time.
Novel drug to stimulate hair regrowth
Hair loss can be caused by various factors. But these factors share one common outcome in that they cause the hair follicles to shrink, which hinders the growth of strong hair.HS-301 induces the proliferation of HHGMCs, the cells responsible for hair growth. This leads to the rapid return of hair follicles to their normal state, enabling strong and sturdy hair growth. For this reason, HS-301 is expected to become the drug of choice for long-term treatment of hair loss, regardless of the cause.
Our vision & values
Hak Bae (Hubert) Choi
Chief Executive Officer
Dae Kyong Kim
Chief Science Officer
Leadership - Key Personnel
Yo Kyung Chung
Senior Vice President,Ph.D.
- Hanmi Pharm. – Sanofi Quantum Project Leader
- Green Cross – Global Project Leader, Process Development Leader
- Daewoong Pharm. – Principal Researcher
- Ph.D. of Biotechnology, Ajou University
- Master Degree of Life Science , Korea University
Jong Hong Hyun
- Avixgen Chief of Management office
- Eluon Head of Finance Team
- Korea Data systems Finance Team member
- Graduated from Department of Accounting at Kyungpook National University
Na Young Park
- HLB LifeScience, Co., Ltd. – BD Director
- Beaumed Co., Ltd. – Senior Manager
- Kunil, Penmix – BD team leader
- JW Holdings, Choongwae Pharma Co.,
- - License, Global Business Team Leader
- Graduated Kyung Hee University, College of Science
Won Mook Kim
- CEO of Aging Life Sciences
- KGII (Korea Genetic Information Institute), QuBest Bio Non-executive director
- COO of Sangjin trading company
- Graduated Seoul National University, College of Pharmacy
Gang Se Lee
- Professional angel investor
- I-sens. Inc Planning and sales director
- Korea Biotech Investment Capital, Head of the Investment Team
- Master's degree in Animal Resource Science at Seoul National University
Vice president, PhD
- GC Pharma, QM/QA Qualified Person
- MOGAM Biotechnology institute, Senior Researcher/Project Leader
- University of Louisville Stem cell Program, Post Doctor
- Samsung Biomedical Research
- Institute, Post Doctor
- Seoul National University, College of Medicine, Immunology, PhD
Dr. med. Yohan Lim, M.D.
- Clinomics Inc. Cancer Institute – Team Leader
- ITREN, Research Prof. at Dankook Univ.
- SIMS, Research Prof. at Soonchunhyang Univ.
- Severance Hospital.– Co-development of Dong-A Pharm..
- Doctor of Medicine at RWTA Aachen School of Medicine, Germany
Leadership - Advisory Board
Dr. Jin Keon Pai
- 1ST Biotherapeutics, Inc. Senior Advisor
- Handok Pharmaceuticals Co., LTD Senior Advisor
- C&C Research Labs. CEO/Executive Vice President
- Senior Principal Scientist, Schering-Plough Research Institute
- Ph. D. of Pharmaceutical Biochemistry
- School of Pharmacy, University of Wisconsin-Madison
Prof. Dong Ho Lee, MD, MBA
- Professor of Medicine at Ulsan University
- CEO of the Korea Drug Development Fund
- Director of the Clinical Research Center at Asan Medical Center
- Business unit head at Samyang
- Medical Director, VP of GSK Korea
Prof. Song Yong Park
- Professor of The Division of Bioscience and Technology at Yonsei University
- Research Director, Mogam Biotech Research Institute
- Executive Director, Green Cross Research Center
- Graduated from Seoul National University Department of Microbiology, doctorate from Ajou University Department of Biotechnology
Prof. Kwang Hoon Lee, M.D. & Ph.D
- Emeritus Professor, Department of Dermatology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Director, Medical Science Research Affairs, Yonsei University
- President, Korean Society for Investigative Dermatology
- Chairman, Board of Directors, Korean Dermatological Association
- President, Korean Atopic Dermatitis Association
- Board of Directors, International Eczema Council
- Member of National Academy of Medicine of Korea
Prof. Sang-Heon Lee, M.D., Ph.D.
- Chairman of Dept. of Internal Medicine, Konkuk University School of Medicine
- Associate Professor, Dept. of Internal Medicine, Kangnam St. Mary’s hospital, the Catholic University of Korea
- Postdoctoral research fellow(Dr. Firestein Lab), Division of Rheumatology, University of California, San Diego
- Director of Planning, Director of Finance, Editorial Chief of Korean College of Rheumatology
- Consultant Physician, Chief of Rheumatic Disease Section, Human Insurance Reimbursement Agency, Korean Ministry of Health and Welfare
- Board Member of Central Drug Review Boards, Korean Food and Drug Administration (KFDA)
- Chief, Auto-immune Research Society [- Korean Society of Immunology]
Prof. Yong Bum Park, M.D.
- Professor, Department of Pulmonary and Critical care Medicine, Kangdong Sacred Heart Hospital Hallym University, Korea
- Associate Professor, Department of Pulmonary and Critical care Medicine, Kangdong Sacred Heart Hospital Hallym University, Korea
- Fellowship of Pulmonary Critical Care Medicine, Dept. of Medicine, Medical Center Ulsan University School of Medicine, Seoul, Korea
- The Asian Pacific Society of Respirology
- The Korean Academy of Tuberculosis and Respiratory Diseases
- The Korean Association of Internal Medicine
전임상시험에 필요한 양 확보, 97% 순도 갖는 대량생산 방법 구축 새로운 기전에 유사물질 없고, 효과 안전성 보장돼 경제성도 긍정적 골관절염·COPD 치료제 내년까지 전임상 마치고 License out 계획...
하플사이언스가 설립 후 처음 주력 파이프라인인 골관절염(퇴행성관절염)치료제 신약 후보물질의 전임상에 착수한다. 당초 올해 2분기에 전임상을 시작하는 일정이었으나 보다 개발에 속도를 높이는 모습이다...
하플사이언스가 HAPLN1을 통해 항노화 치료의 새로운 장을 열고 있어 주목된다. HAPLN1(Hyaluronan And Proteoglycan Link Protein 1)은 TGF-β 시그널링을 활성화해 히알루론산, 콜라겐, 아그레칸의 생성을 증가시키는 인체 내 단백질이다....